Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital downgrades BAT to 'underperform'

(Sharecast News) - RBC Capital Markets downgraded British American Tobacco on Tuesday to 'underperform' from 'sector perform' but lifted the price target to 3,400p from 3,000 as it said profit expectations for the company's New Categories are "seriously overblown". "Our view of the trajectory of BAT's profits and cash flow hasn't changed very much, but given the share price's phenomenal performance, we feel that it is incumbent on us to revisit our assumptions about the drag on profitability we expect from a growing but low margin New Category business," the bank said.

"What we haven't done before is try to dig into the Heated Tobacco, Vapour and Modern Oral markets in any depth, nor compare the relative composition and profitability of BAT and PMI's businesses.

"We recognise that in part BAT's outperformance has been a function of sector rotation, not to mention other consumer staples stalwarts failing to perform in the defensive and predictable manner that has long been a large part of the sector's investment case, in our view.

"But we also think that expectations for the transformational nature of BAT's New Category business have lost touch with the reality of a business that lacks scale in the most profitable New Category (Heated Tobacco) and is most heavily exposed to the competitive battlefield that is Vapour."

RBC said that being so, its expectations for the potential of BAT's profits and cash flow are relatively muted, hence the downgrade.

The bank said it was being a little more generous in its sales forecasts over the next couple of years, with organic revenue growth 2.2% in 2026E and 1.9% in 2027E.

"We assume the 50bps EBIT margin decline kicks in in 2027 and every year thereafter for the purposes of our adjusted present value calculation.

"This yields a price target of £34, up from £30 previously as we have lowered our capex/sales forecast from 3.5% to 2.0%; (if we're right about New Categories' limited profitability potential, it follows that BAT is not going to invest in building capacity at the rate we had assumed)."

At 1100 BST, the shares were down 2.2% at 4,064p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.